XGNHealthcare · Diagnostics & ResearchThe 7 Wall Street analysts covering Exagen, Inc. hold a median 12-month price target of $11 — +29.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 3 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Exagen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on XGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +29.3% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2026 | Canaccord Genuity | Maintains | Buy | $9.00 → $11 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $10 → $11 |
| 5 Aug 2026 | B. Riley Securities | Reiterates | Buy | — |
| 5 Aug 2026 | B. Riley Securities | Reiterates | Buy | $8.00 → $12 |
| 5 Aug 2026 | BTIG | Maintains | Buy | — |
| 5 Aug 2026 | BTIG | Maintains | Buy | $8.00 → $9.00 |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | $8.00 → $10 |
| 25 June 2026 | Roth Capital | Initiates | Buy | $8.00 |
| 25 June 2026 | Roth Capital | Initiates | Buy | — |
| 12 May 2026 | BTIG | Maintains | Buy | — |
| 20 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 11 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 11 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 11 Mar 2026 | Keybanc | Maintains | Overweight | — |
| 10 Mar 2026 | BTIG | Maintains | Buy | — |
| 24 Feb 2026 | TD Cowen | Maintains | Buy | — |
| 17 Feb 2026 | BTIG | Maintains | Buy | — |
| 30 Jan 2026 | B. Riley Securities | Reiterates | Buy | — |
| 10 Nov 2025 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
XGN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Exagen, Inc. returned −21.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 41% of US stocks
Cheaper than 5% of US stocks
Cheaper than 90% of US stocks
Higher than 64% of US stocks
Higher than 55% of US stocks
Higher than 74% of US stocks
Higher than 25% of US stocks
Higher than 14% of US stocks
Higher than 12% of US stocks
Higher than 23% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Exagen, Inc. has a market value of $201.6M and an enterprise value of $206.3M.
Revenue in the twelve months to 30 June 2026: $71.1M. The latest quarter grew 15.9% year on year.
Net income over the same four quarters: −$18.9M, a −26.6% net margin.
Diluted earnings per share, trailing twelve months: $−0.81.
Free cash flow in the twelve months to 30 June 2026: −$7.6M.
Trailing P/E: −8.9×; forward P/E: −17.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Exagen, Inc. employs 216 people — $329K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Exagen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Exagen will participate in the Canaccord Genuity MedTech & Diagnostics Conference on November 11 and the Craig-Hallum Alpha Select Conference on November 17.
Why it matters — The conferences are upcoming events where XGN will participate.
Exagen said it will release financial results for the quarter ended September 30, 2026, before the market opens on November 10, 2026.
Why it matters — XGN watchers may note the scheduled date for the company’s third-quarter financial results.
Exagen reported record second-quarter revenue during its Q2 earnings call, driven by growth in AVISE CTD test volume, average selling price, and Pharma Services revenue. The company came close to achieving adjusted EBITDA break-even.
Why it matters — A stock watcher would care because record revenue across key growth drivers brings the company close to adjusted EBITDA break-even, a notable milestone for its profitability trajectory.
Exagen Inc. held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.
Why it matters — Earnings-call transcripts provide shareholders and analysts with direct insight into management's commentary on the quarter's results and outlook.
Exagen Inc. (XGN) reported a second-quarter loss of $0.13 per share, narrower than the Zacks Consensus Estimate of a $0.19 loss and improved from the $0.18 loss a year ago. The report beat revenue estimates.
Why it matters — The quarter exceeded analyst expectations on earnings and revenue, with a narrower year-over-year loss, making the results noteworthy for Exagen watchers.
The 7 Wall Street analysts covering Exagen, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Exagen, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Exagen, Inc. 56 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Exagen, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +29.3% from the last close, and Ticker Nerd's factor model ranks Exagen, Inc. 56 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Exagen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $12 over the next 12 months.
Exagen, Inc. returned -21.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Exagen Inc. is a commercial-stage diagnostics company focused on autoimmune disease testing.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Exagen Inc. to Participate in Upcoming Investor Conferences". Exagen will participate in the Canaccord Genuity MedTech & Diagnostics Conference on November 11 and the Craig-Hallum Alpha Select Conference on November 17.
Exagen Inc. is a commercial-stage diagnostics company focused on autoimmune disease testing. It develops and commercializes blood-based laboratory tests under its AVISE brand, supporting clinicians in the diagnosis, prognosis, and monitoring of complex rheumatic and autoimmune conditions. Its portfolio is centered on helping healthcare providers assess diseases such as systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s disease with greater clinical clarity. Exagen’s products are used primarily in rheumatology and autoimmune care, where accurate differentiation among overlapping conditions is especially important. The company combines proprietary biomarkers, serology, and cell-based assay technologies to deliver specialized testing solutions for physicians, laboratories, and other healthcare partners. Exagen Inc. plays a focused role in the medical diagnostics market by addressing the needs of patients with chronic autoimmune disorders through specialized laboratory services and branded diagnostic products.
CEO Mr. John Aballi · 216 employees · United States · https://www.exagen.com
